Le Lézard
Classified in: Health, Business
Subject: ERN

Precision Optics Reports Fourth Quarter and Fiscal Year 2022 Financial Results


Conference Call Scheduled for today, September 27, 2022 at 5:00pm ET

GARDNER, Mass., Sept. 27, 2022 /PRNewswire/ -- Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year ended June 30, 2022.

Fourth quarter fiscal 2022 highlights:

Fiscal year 2022 highlights:

Precision Optics' CEO, Joseph Forkey, commented, "Fiscal year 2022 was a transformational year for Precision Optics. We reported record fourth quarter and fiscal year revenues driven by advancement in a number of programs from our pipeline to production, and completed the acquisition of Lighthouse Imaging to combine two of the industry's leaders in micro-optics and digital imaging. We finished out the year with strong quarterly organic revenue growth of 27% year-over-year as we began to see the impact of production increases from new and ongoing programs. As we have long anticipated, gross margins associated with organic revenue have begun to rise as a result of improving production efficiencies along with higher utilization of production and engineering resources."

"In fiscal 2023 we anticipate ongoing revenue and margin growth driven by growth in existing customer programs, new customer programs and Lighthouse programs poised to transfer from product development into production. We continue to invest in our business to build sales and marketing, shift all three business sites to a common and updated operating and financial platform, and supplement our technical team in order to be positioned to take advantage of market trends and opportunities.  In this coming year in addition to continuing our revenue growth we will be focused on demonstrating increasing operating profitability."

"The strategic plan and vision to work with customers at the very early stages of the product development cycle to bring cutting edge technological capabilities in micro-optics, 3D optics and digital imaging to their products is in full effect. This has created a burgeoning production portfolio, which when coupled with a large pipeline of development projects and improved industry trends following the post-pandemic return of elective surgeries, puts us in a tremendous position to continue the progress we have made in fiscal 2022 into the future."

Update on Intent to List Shares on Nasdaq Capital Market

The Company successfully received approval from shareholders at its annual meeting in April 2022 to affect a reverse split if needed to satisfy the Nasdaq minimum share price requirement. The Company believes it has now satisfied all other requirements and is awaiting confirmation, or further comment, from Nasdaq.  With a positive response from Nasdaq, the Company anticipates the process of listing its shares on Nasdaq to be completed in the coming weeks."

The following table summarizes the fourth quarter and fiscal year (unaudited) results for the periods ended June 30, 2022 and 2021:



Three Months


Twelve Months



Ended June 30,


Ended June 30,



2022

2021


2022

2021

Revenues

$  4,793,511

$  2,673,266


$  15,678,248

$  10,674,907








Gross Profit

1,441,363

785,943


4,928,187

3,433,585








Stock Compensation Expenses

150,377

339,718


800,473

620,271

Business Acquisition Expenses

0



162,125


Other

1,711,456

884,657


5,479,480

3,718,887

Total Operating Expenses

1,861,833

1,224,375


6,442,078

4,339,158








Operating Income (Loss)

(420,470)

(438,432)


(1,513,891)

(905,573)








Net Income (Loss)

269,293

(442,443)


(928,418)

(102,826)








Income (Loss) per Share







Basic

$            0.02

$          (0.03)


$            (0.06)

$            (0.01)


Fully Diluted

$            0.02

$          (0.03)


$            (0.06)

$            (0.01)








Weighted Average Common Shares Outstanding






Basic

15,887,161

13,281,351


15,887,161

13,243,595


Fully Diluted

15,887,161

13,281,351


15,887,161

14,068,459

 

Conference Call Details

Date and Time: Tuesday, September 27, 2022, at 5:00pm ET

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/94M6mGLlvKa.

Replay: A teleconference replay of the call will be available until October 4, 2022 at (877) 344-7529 or (412) 317-0088, replay access code 4182019. A webcast replay will be available at https://app.webinar.net/94M6mGLlvKa.

About Precision Optics Corporation

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture.  Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

Non-GAAP Financial Measures

Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net income from continuing operations the effect of Stock-based compensation, Restructuring and other acquisition related expenses and Proceeds from extinguished debt relating to the SBA Payroll Protection Plan loan.

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

About Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Company Contact:                                                    
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Phoenix | New York
Telephone: 602-889-9700
[email protected]

Following are the Company's Consolidated Balance Sheets at June 30, 2022 and June 30, 2021, and Statements of Operations, for the year ended June 30, 2022 and 2021:

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Balance Sheets at June 30, 2022 and 2021




2022



2021


ASSETS









Current Assets:









Cash and cash equivalents


$

605,749



$

861,650


Accounts receivable, net of allowance for doubtful accounts of $44,135 at June 30, 2022
   and $251,383 at June 30, 2021



2,663,872




1,878,755


Inventories



3,022,147




1,885,395


Prepaid expenses



213,448




150,635


Total current assets



6,505,216




4,776,435











Fixed Assets:









Machinery and equipment



3,215,412




3,084,511


Leasehold improvements



843,903




792,723


Furniture and fixtures



219,999




178,640





4,279,314




4,055,874


Less?Accumulated depreciation and amortization



3,651,843




3,461,622


Net fixed assets



627,471




594,252











Operating lease right-to-use asset



517,725




61,247


Patents, net



229,398




141,702


Goodwill



8,824,210




687,664











TOTAL ASSETS


$

16,704,020



$

6,261,300











LIABILITIES AND STOCKHOLDERS' EQUITY









Current Liabilities:









Current portion of capital lease obligation


$

40,705



$

38,347


Current maturities of long-term debt



367,714




?


Current portion of acquisition earn out liability



166,667




166,667


Accounts payable



2,239,175




1,205,149


Customer advances



905,113




450,084


Accrued compensation and other



716,702




589,616


Operating lease liability



150,565




61,247


Total current liabilities



4,586,641




2,511,110











Capital lease obligation, net of current portion



111,691




152,397


Long-term debt, net of current maturities



1,961,141




?


Acquisition earn out liability, net of current portion



705,892




166,666


Operating lease liability, net of current portion



367,160




?











Stockholders' Equity:









Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding ? 16,915,089 shares at June 30, 2022 and 13,282,476 shares at June 30, 2021



169,150




132,825


Additional paid-in capital



56,896,739




50,464,280


Accumulated deficit



(48,094,394)




(47,165,978)


Total stockholders' equity



8,971,495




3,431,127











TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY


$

16,704,020



$

6,261,300


 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

for the Years Ended June 30, 2022 and 2021




2022



2021









Revenues


$

15,678,248



$

10,674,907


Cost of goods sold



10,750,061




7,241,322











Gross profit



4,928,187




3,433,585











Research and development expenses, net



666,479




624,253


Selling, general and administrative expenses



5,613,473




3,714,915


Business acquisition expenses



162,125




?


Total operating expenses



6,442,077




4,339,168











Operating loss



(1,513,890)




(905,583)











Other income (expense)









Interest expense



(155,658)




(5,302)


Gain on forgiveness of bank note



?




808,962


Gain on revaluation of contingent earn-out liability



742,084




?











Loss before provision for income taxes



(927,464)




(101,923)











Provision for income taxes



952




912











Net loss


$

(928,416)



$

(102,835)











Loss per share:









Basic and fully diluted


$

(0.06)



$

(0.01)











Weighted average common shares outstanding:









Basic and fully diluted



15,887,161




13,281,351











 

PRECISION OPTICS CORPORATION, INC AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA






Year Ended June 30


2022


2021

Net income from Continuing operations (GAAP)

$ (928,418)


$ (102,826)

Stock Based Compensation

915,494


733,930

Depreciation & Amortization

190,068


146,926

Interest Expense

159,538


5,302

Income Tax

952


912

Acquisition Expense

162,125


--

Other Income

(742,052)



Proceeds from Extinguished Debt



(808,962)

Adjusted EBITDA (non-GAAP)

$ (242,293)


$   (24,718)

 

SOURCE Precision Optics Corporation


These press releases may also interest you

at 07:28
BioArctic AB (publ) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransportertm technology with an...

at 07:00
LifeLabs workers from Orillia, Barrie, Collingwood, and Wasaga Beach will rally with community members and allies ahead of their imminent strike deadline. They stand firm in their demands for a fair contract that puts patients and workers before...

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...



News published on and distributed by: